| Literature DB >> 20689742 |
Marie Desnos-Ollivier1, Sweta Patel, Adam R Spaulding, Caroline Charlier, Dea Garcia-Hermoso, Kirsten Nielsen, Françoise Dromer.
Abstract
Koch's postulates are criteria establishing a causal relationship between a microbe and a disease that lead to the assumption that diseases are caused by a single strain or its evolved forms. Cryptococcus neoformans is a life-threatening human fungal pathogen responsible for an estimated 1 million cases of cryptococcosis/year, predominantly meningoencephalitis. To assess the molecular diversity of clinical isolates and gain knowledge of C. neoformans biology in the host, we analyzed clinical cultures collected during the prospective CryptoA/D study. Using molecular analysis of unpurified isolates, we demonstrated that mixed infections in humans are more common than previously thought, occurring in almost 20% of patients diagnosed with cryptococcosis. These mixed infections are composed of different mating types, serotypes, and/or genotypes. We also identified genetically related haploid and diploid strains in the same patients. Experimental infections and quantitative PCR show that these ploidy changes can result from endoreplication (duplication of DNA content) and that shuttling between haploid and diploid states can occur, suggesting in vivo evolution. Thus, the concept of one strain/one infection does not hold true for C. neoformans and may apply to other environmentally acquired fungal pathogens. Furthermore, the possibility of mixed and/or evolving infections should be taken into account when developing therapeutic strategies against these pathogens.Entities:
Year: 2010 PMID: 20689742 PMCID: PMC2912664 DOI: 10.1128/mBio.00091-10
Source DB: PubMed Journal: MBio Impact factor: 7.867
Molecular characteristics of C. neoformans isolates causing mixed infections in nine patients with cryptococcosis
| Patient no. and original culture no. | Site of isolation | Days since 1st positive culture | Original culture | Single colonies | ||||
|---|---|---|---|---|---|---|---|---|
| Ploidy | Serotype/mating type | No. studied | Ploidy | Serotype/mating type | MLST profile | |||
| 188 | ||||||||
| AD 1-26 | CSF | 0 | n | Aα | 5 | n | Aα | 7/1/1/13/ |
| AD 1-35 | Urine | 0 | n | Dα | 5 | n | Dα | |
| AD 1-36 | Blood | 0 | n | αADα | 24 | n | Aα | 1/1/1/13/3/21/4/4 |
| AD 1-12 | Blood | 4 | n | Aα | 5 | n | Aα | 7/1/1/13/ |
| AD 1-28 | Blood | 5 | n | Aα | 4 | n | Aα | 7/1/1/13/ |
| AD 1-29 | CSF | 6 | n | Aα | 4 | n | Aα | 7/1/1/13/ |
| AD 1-30 | BAL fluid | 9 | n | Aα | 4 | n | Aα | 7/1/1/13/ |
| AD 1-13 | CSF | 11 | n | Aα | 5 | n | Aα | 7/1/1/13/ |
| AD 1-14 | CSF | 13 | n | Aα | 4 | n | Aα | 7/1/1/13/ |
| AD 1-15 | Blood | 16 | n | Aα | 4 | n | Aα | 7/1/1/13/ |
| 119 | ||||||||
| AD 1-60 | CSF | 0 | n | D | 6 | n | D | |
| 4 | 2n |
| ||||||
| AD 1-61 | Blood | 1 | 2n | D | 4 | 2n |
| |
| 161 | ||||||||
| AD 1-77 | Blood | 0 | n | Aα | 4 | n | Aα | 1/1/3/13/5/19/2/5 |
| 1 | 2n | αAAα | 1/1/3/13/5/19/2/5 | |||||
| AD 1-76 | CSF | 1 | n | αADα | 26 | n | Aα | 1/1/3/13/5/19/2/5 |
| AD 1-78 | CSF | 15 | n | Aα | 5 | n | Aα | 1/1/3/13/5/19/2/5 |
| 20 | ||||||||
| AD 3-28 | CSF | 0 | n | αADα | 9 | n | Aα | 7/1/1/13/ |
| AD 3-29 | Urine | 0 | 2n | Dα | 5 | 2n | αDDα |
|
| 23 | ||||||||
| AD 4-5 | CSF | 0 | n | αADα | 17 | n | Aα | 7/2/1/13/2/19/1/1 |
| 5 | 2n | αDDα |
| |||||
| AD 4-6 | CSF | 15 | 2n | Dα | 5 | 2n | αDDα |
|
| 177 | ||||||||
| AD 4-20 | Skin | 0 | n | Dα | 11 | n | Dα |
|
| 2 | n | Aα | 7/1/1/13/9/19/1/1 | |||||
| AD 4-22 | Urine | 4 | 2n | Dα | 4 | 2n | αDDα |
|
| 1 | 2n | αADα | −/−/−/13/−/−/2/5 | |||||
| AD 4-23 | CSF | 5 | 2n | Dα | 5 | 2n | αDDα |
|
| 71 | ||||||||
| AD 4-24 | CSF | 0 | n | D | 10 | n | D |
|
| AD 4-25 | Urine | 0 | n | D | 5 | n | D |
|
| AD 4-26 | Blood | 0 | n | D | 4 | n | D |
|
| 1 | 2n |
|
| |||||
| AD 4-27 | CSF | 14 | n | αAD | 2 | n | Aα | 1/1/1/13/3/21/4/3 |
| 11 | n | D |
| |||||
| AD 4-64 | CSF | 0 | n | αAD | 10 | n | Aα | 7/1/1/13/ |
| 1 | 2n | αAD | −/−/−/13/−/−/3/ | |||||
| 198 | ||||||||
| AD 6-53 | Blood | 0 | 2n | αAD | 5 | 2n | αAD | −/−/−/13/−/−/3/ |
| AD 4-58 | CSF | 0 | 2n | αAD | 5 | 2n | αAD | −/−/−/13/−/−/3/ |
| AD 5-13 | Blood | 7 | 2n | αAD | 5 | 2n | αAD | −/−/−/13/−/−/3/ |
| AD 5-14 | Blood | 7 | n | Aα | 5 | n | Aα | 1/1/3/13/5/19/2/5 |
Original culture, unpurified culture from clinical sample; single colony, purified single colony from corresponding clinical culture.
Ploidy was determined by flow cytometry; n, haploid; 2n, diploid.
Genotypes were determined for serotype A and serotype D isolates by using eight loci selected by the MLST method. For AD hybrid isolates, allelic profiles were determined for CAP10 and URE1 (27) and for SOD1, PLB1, and TEF1 loci with serotype A-specific primers specifically designed for this study. All of the AD hybrid and Aα strains studied had the same nucleotide sequences for the CAP10 and URE1 loci. New alleles are in bold italics, serotype D alleles are underlined, and serotype A alleles are without underlining.
Characteristics of patients with and without mixed cryptococcal infections
| Patient characteristic | Value for patients with: | ||
|---|---|---|---|
| Mixed infection ( | No mixed infection ( | ||
| No. of males/total | 9/9 (100) | 34/40 (85) | 0.577 |
| Mean age (yr) ± SD | 44 ± 12 | 44 ± 14 | 0.912 |
| No. HIV infected/total (%) | 7/9 (78) | 30/40 (75) | 1.000 |
| No. HIV positive with antiretroviral therapy /total (%) | 2/7 (29) | 12/29 (41) | 0.681 |
| No. born in Africa/total (%) | 1/9 (11) | 4/40 (10) | 1.000 |
| Presentation at baseline | |||
| No. with abnormal neurology/total (%) | 4/9 (44) | 15/40 (37.5) | 0.720 |
| No. with meningoencephalitis/total (%) | 9/9 (100) | 29/34 (83) | 0.319 |
| No. with fungemia/total (%) | 5/9 (56) | 17/38 (45) | 0.715 |
| No. with dissemination/total (%) | 7/9 (78) | 24/40 (60) | 0.454 |
| No. with high serum antigen titer (≥512)/total (%) | 4/9 (44) | 13/36 (37) | 0.716 |
| No. with abnormal brain imaging/total (%) | 2/9 (22) | 8/29 (26) | 1.000 |
| No. with mycological failure at day 15 | 5/8 (62.5) | 10/32 (31.2) | 0.126 |
| No. who died within 90 days after diagnosis/total (%) | 0/8 | 9/37 (24) | 0.179 |
Total number of patients evaluated or for whom the information was available.
Persistence of viable cryptococci in cultured samples.
FIG 1 Comparison of DNA contents and virulence of haploid and diploid Aα C. neoformans isolates recovered during human or murine infections. (A) Cells were stained with propidium iodide to measure DNA content in comparison with that of reference haploid strain H99. Ploidy was determined for single-colony isolates (AD 7-99 and AD 8-18) purified from clinical sample AD 1-77, as well as a single colony (AD 10-30) recovered from the brain of a mouse inoculated with AD 7-99. (B) Three groups of seven outbred male mice were inoculated intravenously with 105 cells of haploid (AD 7-99) or diploid (AD 8-18) strains purified from the clinical sample or the diploid strain (AD 10-30) recovered from the mouse brain. Differences in survival were analyzed using Stata (SE) version 10 (Stata Corporation, College Station, TX). The strains of clinical origin showed no statistically significant differences in virulence (P = 0.056). Mice infected with the diploid strain of murine origin (AD 10-30) survived significantly longer than did mice infected with the strains of clinical origin (P < 0.001, log-rank test).
FIG 2 Colocalization of different strains following intravenous inoculation. C. neoformans strains KN99a and KN99α were stained with Alexa Fluor 594 (red) and 350 (blue), respectively. Mice were inoculated via the tail vein with 5 × 106 KN99a cells and then 5 × 106 KN99α cells. At 24 h postinoculation, the animals were sacrificed and their brains were harvested for immunofluorescence. Frozen sections were immunostained with anti-collagen IV primary antibody with an FITC (green)-labeled secondary antibody to identify capillary endothelial cells. Bar, 20 µm.
Evaluation of CHS1 and NAT gene copy numbers for haploid and diploid isolates recovered from infected mouse tissues by quantitative PCR
| Strain(s) and DNA amt |
|
|
|
|---|---|---|---|
| NAT-resistant haploid AD 1-25 | |||
| 100 ng | 23.99 | 23.12 | 1.038 |
| 50 ng | 25.29 | 24.99 | 1.012 |
| 20 ng | 28.69 | 27.58 | 1.040 |
| 10 ng | 29.70 | 28.54 | 1.041 |
| 5 ng | 30.89 | 29.88 | 1.034 |
| 2 ng | 32.79 | 31.56 | 1.039 |
| 1 ng | 34.78 | 32.48 | 1.071 |
| Wild-type haploid AD 7-99 | 26.27 | 35 | |
| NAT-resistant haploid isolates from infected tissues ( | 27.35 ± 1.48 | 26.43 ± 1.38 | 1.03 ± 0.02 |
| NAT-resistant diploid isolates from infected tissues ( | 26.43 ± 2.00 | 25.59 ± 1.78 | 1.03 ± 0.02 |
Cp, crossing point.
Values are means ± standard deviations.
Sequences of primers designed for MLST locus SOD1 specific for serotype D, for MLST loci PLB1 and TEF1 specific for serotype A, for NAT insertion, and for quantitative PCR
| Locus | Primer | Sequence (5′–3′) | Amplicon size (bp) |
|---|---|---|---|
|
| SOD1Df | TCTAGTCAAAATGGTCAAGG | 643 |
| SOD1Dr | CGCAGCCGTTCGTTTGGACG | ||
|
| PLB1serAf | GCCACGGGTACTTTTGC | 821 |
| PLB1serAr | CGCTCGGGTAAAACATGAG | ||
|
| TEF1f | AATCGTCAAGGAGACCAACG | 993 |
| TEF1serAr | GCTCTTCCCATCGGACTTC | ||
| 5′ flanking region for | KN0140 | TGCTCACATCCTCGCAGCACACCACAGATCCAAAACCC | |
| KN0129 | GCAACCTTGGTTTGAAGAGC | ||
| 3′ flanking region for | KN0139 | CCGTGTTAATACAGATAAACCCGAAGGGACCAGTCACAAGT | |
| KN0122 | AACCTGACGGAAGAGCAGAA | ||
| Outside 5′ integration check | KN0177 | CGTCATCAAACCTAGCAGCATTCG | |
| Outside 3′ integration check | KN0176 | CTCGAGACCAAGATCAAGATTGCC | |
|
| CHS1f | GTCCCAGGAGGACTCCTTTC | 168 |
| CHS1r | TGTCGTTCAGGTCGAGTGAG | ||
|
| KN0192 | GGTGACGCGGAAGACGGTGT | 123 |
| MD001 | GTATGGCGGCCGCCACTCT |